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Protein dynamicsTheα7 nicotinic acetylcholine receptor (nAChR), assembled as homomeric pentameric ligand-gated ion channels,
is one of the most abundant nAChR subtypes in the brain. Despite its importance in memory, learning and
cognition, no structure has been determined for the α7 nAChR TM domain, a target for allosteric modulators.
Using solution state NMR, we determined the structure of the human α7 nAChR TM domain (PDB ID: 2MAW)
and demonstrated that theα7 TM domain formed functional channels in Xenopus oocytes.We identiﬁed the asso-
ciated binding sites for the anesthetics halothane and ketamine; the former cannot sensitively inhibitα7 function,
but the latter can. Theα7 TMdomain folds into the expected four-helical bundlemotif, but the intra-subunit cavity
at the extracellular end of the α7 TM domain is smaller than the equivalent cavity in the α4β2 nAChRs (PDB IDs:
2LLY; 2LM2).Neither drug binds to the extracellular end of theα7 TMdomain, but twohalothanemolecules or one
ketamine molecule binds to the intracellular end of theα7 TM domain. Halothane and ketamine binding sites are
partially overlapped. Ketamine, but not halothane, perturbed the α7 channel-gate residue L9′. Furthermore, halo-
thane did not induce profound dynamics changes in theα7 channel as observed inα4β2. The study offers a novel
high-resolution structure for the humanα7 nAChR TM domain that is invaluable for developing α7-speciﬁc ther-
apeutics. It also provides evidence to support the hypothesis: only when anesthetic binding perturbs the channel
pore or alters the channel motion, can binding generate functional consequences.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Nicotinic acetylcholine receptors (nAChRs) belong to a superfamily
of pentameric ligand-gated ion channels (pLGICs), including 5HT3,
GABAA, and glycine receptors, that mediate fast synaptic transmission
in the central and peripheral nervous systems. The α7 nAChR is one of
the most abundant nAChR subtypes in the brain and assembles as
homomeric functional pentamers [1]. High expression levels of the α7
nAChR have been observed in brain regions involved in learning,
memory, and cognition [2,3]. Therefore, theα7 nAChR is a viable target
for therapeutics to regulate processes impaired in schizophrenia,
Alzheimer's disease, and other neurological disorders [4,5]. α7 nAChR
is also a target for therapeutic modulation of angiogenesis and inﬂam-
mation [6,7].
In order to rationally design therapeutics speciﬁcally targeting the
α7 nAChR, a high-resolution structure ofα7 is highly desired. However,
no experimental structure for the full-lengthα7 nAChR currently exists.
The highest degree of structural information for α7 nAChR has beenTower 3, 3501 Fifth Avenue,
, USA. Tel.: +1 412 383 9798;
ights reserved.achieved for the extracellular (EC) domain, which contains the
orthosteric ligand-binding site. X-ray structures of chimeras that have
systematically modiﬁed the sequence of acetylcholine binding proteins
[8–10] toward the human α7 nAChR provide invaluable atomic details
for theα7 EC domain [11,12]. The overall topology and structural infor-
mation for the transmembrane (TM) domain and the intracellular (IC)
domain of α7 nAChR have relied on the 4-Å resolution model of the
Torpedo marmarota nAChR determined by cryo-electron microscopy
[13]. Recent crystal structures of homologous bacterial pLGICs from
Erwinia chrysanthemi (ELIC) [14] and Gloebacter violaceous (GLIC)
[15,16] as well as the Caenorhabditis elegans glutamate-gated chloride
channel (GluCl) [17], have also added valuable structural templates
for modeling pLGICs.
Previous molecular models for the α7 nAChR [18,19] were based on
structures of the Torpedo marmarota nAChR [13]. Homology modeling
can capture overall structural features that are likely sufﬁcient for
many purposes, but it may miss speciﬁc structural details that can dif-
ferentiate functions and pharmacology of different nAChR subtypes.
For example, the α7 and α4β2 nAChRs would have similar structural
models, which cannot provide sufﬁcient insights for reasoning why
α7 is insensitive but α4β2 is hypersensitive to functional modulation
by volatile anesthetics [20,21]. Reliable structures for individual sub-
types of nAChRs, especially their TM domains, are also important for
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tential, such as PNU-120596 [22–24] and TQS [25,26]. They are speciﬁc
modulators for α7 nAChRs and have virtually no effect on other nAChR
subtypes.
In the study reported here, we determined the structure of the human
α7 nAChR TM domain using high-resolution solution state NMR. The
structures newly determined for α7 and previously determined for
α4β2 nAChRs (PDB codes: 2LLY; 2LM2) [27] offer an opportunity to
make structural comparisons and to reveal a structural basis that differen-
tiates function andpharmacologyof different nAChR subtypes. In addition
to the new structure for α7, we also determined binding sites in α7 for
the volatile anesthetic halothane and the intravenous anesthetic
ketamine. The identiﬁed structural and dynamics determinants from the
study have general implication for anesthetic action in pLGICs.
2. Materials and methods
2.1. Sample preparations
The humanα7 nAChR TM domain for the NMR study contained 137
residues (Fig. S1). In order to reduce complexity of the NMR spectra, the
cytoplasmic loop between TM3 and TM4 was replaced with GGGEG, a
sequence designed to avoid imposing structural constraints on interac-
tions of the TMheliceswhile providing a hydrophilic surface to enhance
stability of the isolated TM domain. The TM3-4 loop of α7 nAChR is
involved in receptor assembly and trafﬁcking to the cell surface in
eukaryotes [28,29], but studies with related pLGICs have established
that the TM3-4 loop is not essential for channel function [30]. Glutamate
mutations at the N- and C-termini (Fig. S1), designed to lower the pI of
the construct, were necessary to secure protein stability for NMR mea-
surements. Additional mutation of three hydrophobic residues to serine
within the TM2–TM3 linker (Fig. S1) was also instrumental to prevent
protein destabilization, similar to the previous observation on α4β2
TMdomains [27]. Without thesemutations, the isolated α7 TM domain
had a tendency to aggregate on puriﬁcation, most likely because hydro-
phobic residues normally shielded by the EC domain were exposed to
solvent.
The same protocol as reported previously [27] was used for the α7
expression and puriﬁcation. The protein was expressed in Escherichia
coli Rosetta 2(DE3) pLysS (Novagen) at 15 °C for three days using the
Marley protocol [31]. The protein was puriﬁed in LDAO using his-tag
afﬁnity column before and after cleavage of the his-tagged region. Each
NMR sample contained 0.25–0.3 mM α7, 1–2% (40–80 mM) LDAO
detergent, 5 mM sodium acetate at pH 4.7, 10 mM NaCl, and 20 mM
2-mercaptoethanol to prevent disulﬁde bond formation. 5% D2O was
added for deuterium lock inNMRexperiments. The anesthetics ketamine
(80–240 μM) or halothane (0.7–5.5 mM)were titrated into the samples
using a micropipette or a gas-tight microsyringe, respectively. The con-
centration of the volatile anesthetic halothane was quantiﬁed based on
19F NMR using the method reported previously [32].
2.2. NMR spectroscopy
NMR spectra were acquired on Bruker Avance 600 and 800 MHz
spectrometers at 45 °C using triple-resonance inverse-detection cryo-
probes (Bruker Instruments, Billerica, MA). For 1H, 15N, and 13C chemical
shift assignment and the protein structure determination, a suite of NMR
experiments were performed: HNCA (1024 × 28 × 72) and HN(CO)CA
(1024 × 28 × 54), both with spectral windows of 1H-12 ppm, 15N-
20.5 ppm, 13C-19 ppm; HNCO (1024 × 32 × 40) with spectral widths
of 1H-11 ppm, 15N-22 ppm, and 13C-10 ppm; 15N-edited NOESY
(1024 × 36 × 104) with spectral windows of 1H-11 ppm and 15N-
22 ppm, and a mixing time of 120 ms; 1H–13C HSQC (1024 × 256)
with spectral windows of 1H-11 ppm and 13C-64 ppm; and 1H–15N
TROSY–HSQC (1024 × 128) with spectral windows of 1H-11 ppm and
15N-22 ppm. HSQC spectra showing temperature dependence of amideproton chemical shifts were collected at 35, 40, and 45 °C. Residues
of temperature coefﬁcients below 4.5 ppb/K were considered to be in
helical structure and involved in hydrogen bonds [33].
1H–15N TROSY–HSQC spectra were acquired at 600 MHz in the ab-
sence and presence of the anesthetics halothane or ketamine. Direct
contacts of halothane with theα7 TM domain were determined by sat-
uration transfer difference (STD) spectra [34]. A series of 1D STD spectra
with different saturation times were collected in an interleaved fashion
with on- and off-resonance frequencies of 0.4 ppmand 25 ppm, respec-
tively. A recycle delay of 12 s and 64 scanswere used for each STD spec-
trum. 2D saturation transfer spectra [35] were acquired in the presence
of 3.2 mM halothane in an interleaved fashion with on- and off-1H
resonance frequencies of 6.48 ppm (the halothane proton frequency)
and 25 ppm(blank), respectively. The selective saturationwas achieved
using an IBURP2 pulse train (50 ms Gaus1.1000-shaped with an
interpulse delay of 4 μs). The total saturation timewas 2 s and a recycle
delay was 3 s. The 1H chemical shifts were referenced to the DSS
resonance at 0 ppmand the 15N and 13C chemical shiftswere referenced
indirectly [36].
2.3. Structure calculation and analysis
NMR data were processed using NMRPipe 4.1 and NMRDraw 1.8
[37] and analyzed using Sparky 3.10 [38]. 1H, 15N, and 13C chemical
shift assignments were performed manually. NOE cross-peak assign-
ment was initially carried out manually and more cross-peaks were
assigned later by CYANA 2.1 [39]. CYANA 3.0was used for structural cal-
culations. A total of 100 structures were calculated based on NOE and
hydrogen-bonding restraints as well as TALOS dihedral angle restraints
derived from the chemical shifts [40]. Of the 100 structures, 25 struc-
tures with the lowest target function were used for further reﬁnement
in CYANA 3.0. The 20 structures with the lowest target function after
reﬁnement were analyzed using VMD [41] and Molmol [42].
Contactmap analysis (CMA) [43] was used for comparison of theα7
TM tertiary structureswith structures of other homologous proteins. In-
ternal cavities in theα7 TMdomain were determined for each of the 20
NMR structures using the POVME algorithm [44]. Grids for cavities at
the EC and IC ends of the nAChR TM domains were generated with
0.5 Å grid spacing. The mean ± standard error calculated based on
cavity volumes for the 20 NMR structures is reported.
2.4. Visualization and molecular docking of anesthetics in the α7 nAChR
To assist with visualizing halothane- and ketamine-binding sites
identiﬁed by NMR experiments, we performed targeted anesthetic
docking to the α7 NMR structures. The targeted docking kept only
those sites consistent with the NMR results. Docking was performed
with Autodock4 [45] using a Lamarckian genetic algorithm with a grid
spacing of 0.375 Å. For each binding site suggested by NMR, 250
independent anesthetic dockings were performed within a cube cover-
ing ~6600 Å3 located at the IC end of the TM domain. Each docking
calculation used an initial population size of 500.
2.5. Size exclusion chromatography–multi-angle light scattering
(SEC–MALS) analysis
Oligomerization states of the α7 TM domain in the NMR samples
were determined using size exclusion chromatography (Superdex 200
10/300, GE Healthcare) coupled with multi-angle light scattering
(HELEOS, Wyatt Technology), UV (Agilent 1100 Series; Agilent Technol-
ogy), and differential refractive index (Optilab rEX; Wyatt Technology)
detection. The molar mass of the protein-detergent complex was deter-
mined using ASTRA software (Wyatt Technology) [46]. The conjugate
analysis module of ASTRA was used to differentiate contributions of the
protein and detergent to the molecular weight. The speciﬁc refractive
index (dn/dc) values of 0.185 and 0.148 were used for the protein and
A B C
Fig. 2. NMR structures of the α7 TM domain. (A) A bundle of the 20 lowest-energy struc-
tures of theα7 TM domain (PDB ID: 2MAW). The structures are colored from red for TM1
to blue for TM4. The backbone atomRMSD for the helical regions is 1.24 ± 0.32 Å. Full sta-
tistics for the α7 structure calculations are summarized in Table S1. (B) Overlay of repre-
sentative structures of α7 (blue) and α4 (yellow; PDB ID: 2LLY). The backbone atom
RMSD for the helical regions ofα7 andα4 is 2.9 Å. (C)Overlay of representative structures
ofα7 (blue) andβ2 (green; PDB ID: 2LM2). The backbone atomRMSDbetween the helical
regions of α7 and β2 is 2.1 Å.
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was calculated based on the α7 sequence. A measured UV extinction
coefﬁcient of 0.06 for a 1% solution at 280 nm was used for LDAO.
2.6. Functional measurements in Xenopus oocytes
Puriﬁed α7 TM domain in LDAO detergent was reconstituted into
asolectin vesicles by adsorption of detergent using Bio-Beads SM-2
non-polar polystyrene adsorbent (Biorad) in the presence of a 100:1
molar ratio of asolectin to protein following themanufacturer's instruc-
tions. The prepared vesicles (50 nl) containing 100 ng ofα7 TMdomain
were injected into Xenopus laevis oocytes (stages 5–6). Oocytes were
maintained in modiﬁed Barth's solution containing 88 mMNaCl, 1 mM
KCl, 2.4 mMNaHCO3, 15 mMHEPES, 0.3 mMCa(NO3)2, 0.41 mMCaCl2,
0.82 mM MgSO4, 10 μg/ml sodium penicillin, 10 μg/ml streptomycin
sulfate, and 100 μg/ml gentamycin sulfate, pH 6.7 at 18 °C. After 1–
3 days, channel function was measured by two-electrode voltage
clamp experiments [48]. Oocytes in a 20-μl oocyte recording chamber
(Automate Scientiﬁc) were clamped at −60 mV with an OC-725C
Ampliﬁer (Warner Instruments) and currents were elicited using iver-
mectin as an agonist. The recording solutions contained 130 mM NaCl,
0.1 mM CaCl2, 10 mMHEPES, pH 7.0 with the indicated concentrations
of ivermectin and ketamine. Data were collected and processed using
Clampex 10 software (Molecular Devices).
3. Results
3.1. NMR structures of the human α7 nAChR TM domain
The α7 TM domain spontaneously assembled into pentamers in
LDAO (Fig. S2) and formed ion-conducting channels when the puriﬁed
α7 TM domain was injected into Xenopus oocytes as reconstituted
asolectin vesicles (Fig. 1). Although theα7 TMdomain does not possess
the orthosteric agonist-binding site of native human α7 nAChR, the
channel current could be elicited by ivermectin, a known positive allo-
steric modulator acting through the TM domain [49,50]. Ketamine
inhibited ivermectin-induced current (Fig. 1B), consistent with the
effect of ketamine on native human α7 nAChR [51–53]. No
ivermectin-elicited current was observed in control oocytes injected
with the asolectin vesicles not containing the α7 TM domain. These
data demonstrate that the α7 TM domain retains pharmacological
responses observed for the full-length α7 nAChR.
NMR spectra of theα7 TM domain permitted assignment of ~95% of
its residues (Fig. S3). A bundle of the 20 lowest target functionFig. 1. Representative traces for Xenopus oocytes injected with vesicles containing the
puriﬁed humanα7 nAChR TM domain. (A) Current response at 10 and 30 μM ivermectin.
(B) Inhibition of ivermectin (30 μM)-elicited current by 100-μM ketamine. Bars over the
trace indicate length of application of the indicated compounds. Scale bars indicate
0.5 min and 0.1 μA.structures of the α7 TM domain (PDB code: 2MAW), as shown in
Fig. 2A, were determined based on short-, medium-, and long-range
NOEs, dihedral angle constraints, and hydrogen bonding constraints
(Fig. S4). The average pair-wise root mean square deviations (RMSD)
in the helical regions are 1.24 ± 0.32 Å for the backbone and
1.64 ± 0.30 Å for all heavy atoms. Detailed statistics of structural
calculations are provided in Table S1.
The tertiary structure of the α7 TM domain resembles those deter-
mined previously for the α4β2 (PDB IDs: 2LLY; 2LM2) nAChR [27] and
several other homologous pLGICs [14–17]. However, small structural
differences can be observed among the nAChR TM domains in the con-
tact map analysis (Fig. S5). The angles between TM2 and TM4 helices
are 3.9 ± 0.5° in α7, but 8.8 ± 0.9° and 10.5 ± 1.1° in α4 and β2,
respectively. The angles between TM1 and TM3 helices are 3.8 ± 0.7°
in α7, but 5.3 ± 0.6° and 5.7 ± 0.7° in α4 and β2, respectively. Struc-
tural alignment of α7 onto α4 or β2 (Fig. 2B and C) shows that the α7
structure is more compact at the EC end of the TM domain, where α7
has an intra-subunit cavity with a volume of 122 ± 10 Å3. In contrast,
α4 and β2 have larger cavities in the same region with volumes of
232 ± 6 Å3 and 179 ± 12 Å3, respectively. The structural differences
at the IC end of the TM domain seem to be reversed. The intra-subunit
cavities at the IC end of the TM domains have volumes of 209 ± 8 Å3,
139 ± 11 Å3, and 131 ± 10 Å3 for α7, α4, and β2, respectively.3.2. Halothane binding site in the human α7 nAChR TM domain
The anesthetic halothane directly interacts with the α7 TM domain.
As shown in the STD spectra ofα7 acquired in the presence of halothane
(Fig. 3), intensity of the halothane signal is modulated by different
saturation times for the α7 signals. A longer saturation time for the se-
lected α7 protons (0.4 ppm) resulted in greater attenuation of the hal-
othane signal due to effective saturation transfer from protein to ligand.
Consequently, the net halothane signal in the STD spectra increased,
because a STD spectrum resulted from subtraction of a pair of spectra
acquired in an interleaved fashion with saturation off-resonance
(25 ppm) and on-resonance (0.4 ppm). In the absence of α7, no halo-
thane signal was detected in the STD spectra under the same NMR ex-
perimental condition (Fig. S6), conﬁrming that halothane signals in
Fig. 3A result predominately fromdirect halothane interactionswithα7.
Fig. 3. Saturation transfer difference (STD) spectra of the α7 TM domain for halothane
binding. (A) Prolonged saturation time increased halothane (3.2 mM) signal in the STD
spectra in the presence of α7. The STD spectra resulted from the subtraction of the off-
(25 ppm; blank region) from the on-resonance (0.4 ppm; protein methyl group) spectra.
(B) STD ampliﬁcation (%) as a function of the saturation time. STD ampliﬁcation is deﬁned
as (Voff − Von)/Voff, Voff and Von are the integrals of halothane peak in the spectrawith off-
and on-resonance saturation, respectively.
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Fig. 4.Halothane binding sites in the TMdomain of thehumanα7nAChR. (A)Overlay of 2D
saturation transfer NMR spectra ofα7 acquiredwith 1H saturation frequency on (cyan) and
off (purple) the proton resonance of halothane (3.2 mM). Residues showing considerable
decreases in their peak intensities upon saturation of the halothane signal are labeled
with the one-letter amino acid code and the sequence number. (B) Overlay of 1H–15N
TROSY–HSQC spectra of α7 in the absence (red) and the presence (green) of halothane
(1.7 mM). Residues showing signiﬁcant changes in chemical shift or relative peak intensity
are labeled. (C) Side and (D) top views of theα7 structure highlighting the residues affected
by halothane in (A) and (B) using purple and blue sticks, respectively. Two halothanemol-
ecules are shown in silver surface.
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performed 2D saturation transfer NMR experiments, in which the α7
spectra in the presence of halothane were acquired in an interleaved
fashion with the 1H saturation frequencies at 6.48 ppm (the halothane
proton frequency) and 25 ppm (blank), respectively. When halothane
was saturated, residues showing substantial decrease in their peak
intensities should be in close contact with halothane (Fig. 4A). These
residues include F230 in TM1, K239 in TM2, and F453 and C449 in
TM4. The full spectra of the 2D saturation transfer experiments are
provided in Fig. S7.
1H–15N TROSYHSQC spectra ofα7were acquired in the absence and
presence of halothane (Figs. 4B and S8). Several residues, including
C219, V220, S223 of TM1, K239 of TM2, and T289 of TM3, show notable
changes after the addition of halothane. When these residues along
with those identiﬁed in saturation transfer experiments are mapped
onto the α7 structure, halothane binding to an intra-subunit cavity
becomes clear (Fig. 4C). The upper part of the cavity is located at the
middle of the TM domain and lined by residues from TM1, TM3, and
TM4. The lower part of the cavity is located at the IC end of the TM do-
main and lined with residues from TM1, TM2, and TM3. The cavity size
is large enough for hosting two halothane molecules. This site is similar
to one of the sites observed in the α4β2 nAChR [54]. However, unlike
α4β2, α7 does not have halothane bound to the EC end of the TM
domain. The different binding sites may account for high functional
sensitivity of the α4β2 nAChR and low functional sensitivity of α7
nAChR to halothane [20,21].3.3. Ketamine binding sites in the human α7 nAChR TM domain
Because of severe signal overlap between ketamine andα7 in the 1H
spectra, the saturation transfer experiments cannot be performed on
ketamine inα7. Thus, we compared theα7 1H–15N TROSYHSQC spectra
in the absence and presence of ketamine to identify ketamine binding
sites. Residues showing signiﬁcant changes in the spectra upon keta-
mine binding are highlighted (Figs. 5A and S9) and mapped onto the
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the lower half of the TM domain, similar to the case for halothane
(Fig. 4C). It is noteworthy that the binding sites for ketamine and halo-
thane largely overlap, but these two drugs perturbed different residues
in this relatively large cavity near the IC end of the α7 TM domain. For
example, F453, S285, I217, and L248 had obvious changes in their chem-
ical shifts upon adding 80-μM ketamine, but the same change was not
observed when 3.2-mM halothane was added to the sample (Fig. 4B).
Conversely, C219, S223, and T289 showed changes in their chemical
shifts only upon the addition of halothane, but not ketamine. Only a sin-
gle ketamine molecule can ﬁt into the cavity because of the larger mo-
lecular volume of ketamine. In contrast, the cavity can host two
halothane molecules simultaneously. One of the most notable differ-
ences between ketamine and halothane binding is that ketamine, but
not halothane, introduced changes to the pore-lining residue L248
(L9′ using the conventional prime numbering system). L9′ is a key res-
idue in the channel gate. Its chemical shift change signiﬁes perturbation
to the channel gate, which will most likely generate a functional
consequence.
The half maximal inhibitory concentration (IC50) of halothane is
~1200 μM for the α7 nAChR [21], but only ~27 μM for the α4β2
nAChR [55]. The IC50 values of ketamine for the α7 and α4β2 nAChRs
are ~20 μM and 50–72 μM [52,53], respectively. Anesthetic concentra-
tions used for functional measurements are typically referred to theconcentrations measured in saline. If one considers a membrane/saline
partition coefﬁcient of ~100 for anesthetics [56,57], halothane and keta-
mine concentrations used for our NMR experiments, in the presence of
the LDAOmicelles, are reasonably close to those used for anesthetic in-
hibition of nAChRs. Thus, the observed anesthetic-induced changes in
the NMR experiments are likely relevant to functional modulation by
the anesthetics.
3.4. Anesthetics modulation of the α7 dynamics
Upon adding anesthetics to α7, relative amide peak intensities of
some residues increased or decreased in the α7 NMR spectra
(Fig. S10), indicating changes in protein dynamics [54,58,59]. Residues
lining the binding site for halothane or ketamine tended to experience
intensity decrease, while residues distant from the binding sites had in-
tensity decrease or increase (Fig. 6). Among residues whose intensity
changed more than 25%, halothane binding decreased intensity for 7
out of 10 residues; those in TM2 and TM3 decreased exclusively. In con-
trast, six out of 11 residues having more than 25% intensity changes in
response to ketamine binding experienced peak intensity increase. An-
other notable difference between halothane and ketamine binding is
the number of residues in TM4 affected by ketamine (R447, F453,
S447, I458, and T461) andhalothane (C449). The profoundperturbation
to TM4 is expected to introduce functional consequences [60–62]. The
role of TM4 in Cys-loop receptor-lipid interactions as well as in nAChR
function has been established [60–63].
Peak splitting was observed previously in NMR spectra of the α4β2
nAChR TMdomain in the presence of anesthetics [54]. The splitting like-
ly indicates a shift of conformational exchange from intermediate (or
fast) to slow time scale. It is noteworthy that the splitting observed on
α4β2 did not occur on α7 (Fig. 6C). Neither halothane nor ketamine
was able to drive α7 into slow conformational exchange mode as they
did on α4β2.
4. Discussion
4.1. Small structural differences can make profound functional impact
The NMR structure reported here offers valuable spatial details spe-
ciﬁcally for the human α7 nAChR TM domain that may not have been
accurately captured by computer modeling. Although pLGICs share a
common scaffold, variations in the TM helical lengths and orientations
among various pLGICs exist. Even for the TM domains of the α7, α4,
and β2 nAChRs that share sequence identities up to ~50%, structural de-
viations in their TMdomains are observable. Differences in helical tilting
in the range of 5 to 7° were observed that could account for differences
in intra-subunit cavities and helical packing (Fig. 2, Fig. S5). Can these
seemingly subtle structural variances generate impact to drug binding
and channel functions? Unwin and Fujiyoshi recently reported gating
movement of Torpedo nAChR caught by plunge-freezing [64]. The EM
images show only a small magnitude structural displacement for the
closed- and open-channel nAChRs, in which no more than a 2° tilt and
a 2 Å shift were found in the pore-lining helices [64]. Furthermore,
open and locally closed crystal structures of GLIC revealed only a ~6° dif-
ference in the TM2 tilting angles [65]. Hence, a subtle structural change
is not unexpected for a profound functional difference. Following the
same principle, a subtle structural differencemay be sufﬁcient for deﬁn-
ing pharmacological characteristics of individual receptors. Indeed, our
recent study onα7β2 demonstrated that the subtle structure difference
at the EC end of the TM domain produced a profound impact to
isoﬂurane binding and inhibition [66]. Furthermore, certain positive
allosteric modulators interacting at an intra-subunit TM site, such as
PNU-120596 [22–24] and TQS [25,26], are known to have direct
modulatory effects only on α7 nAChRs, but virtually no effect on other
subtypes of nAChRs.
Fig. 6.Anesthetic effects on backbone dynamics of the TM domain of the humanα7 nAChR. Residues, whose relative peak intensity increased (red) or decreased (blue) upon the addition
of (A) halothane (silver surface) and (B) ketamine (cyan surface) binding, are highlighted in the α7 structure. (C) Representative regions of 1H–15N TROSY–HSQC spectra in the absence
(red or black) and presence (green or blue) of halothane. α7-V229 (top, left) is equivalent toα4-V236 (bottom, left); α7-L215 (top, right) is equivalent to β2-L216 (bottom, right). Note
the halothane-induced peak splitting in α4-V236 and β2-L216, a sign of decrease of conformational exchange rates by halothane. Such changes were not observed in α7.
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The α7 and α4β2 nAChRs are the two most abundant nAChR sub-
types in the brain. Previous investigations indicate that the α7 nAChR,
unlike theα4β2 nAChR, has distinct low functional sensitivity to volatile
anesthetics, such as halothane [20,21]. The reason why volatile anes-
thetics are ineffective on α7 but effective on α4β2 has been a mystery
in the past. Here, we have determined the α7 NMR structures (Fig. 2)
and a halothane-binding site in α7 (Fig. 4). We showed that α7 does
not have a binding site for halothane at the EC end of the TM domain
as revealed previously for α4β2 [54]. Furthermore, we have disclosed
an association of anestheticmodulation on channel dynamics and chan-
nel function (Fig. 6). Comparisons of structural, dynamics, and anesthet-
ic binding information between α7 and α4β2 offer a clue for reasoning
why α7 is insensitive to halothane and other volatile anesthetics.
Halothane binds to α7 (Figs. 3, 4), but the binding to the IC end of the
TM domain did not effectively modulate dynamics of channel residues
as it did in α4β2 (Fig. 6), where more profound dynamics changes
were observed. These results suggest a plausible association between
dynamics modulation and functional modulation by anesthetics.
Anesthetic binding would not produce functional impact unless the
binding can signiﬁcantly alter channel motions coupled with functions.
4.3. Ketamine action site in the α7 nAChR
The functional insensitivity ofα7 to halothane or other volatile anes-
thetics may result from an inability to effectively modulate channel dy-
namics due to anesthetic binding to the IC end of the TMdomain and/or
lack of anesthetic binding to the EC end of theα7 TMdomain. However,
the intravenous anesthetic ketamine binds to the α7 TM domain site;
yet ketamine inhibits the α7 nAChR with a similar inhibition efﬁcacy
as it acts on the α4β2 nAChRs [51–53]. It is possible that with its larger
molecular size, ketamine can accomplish what halothane and other
volatile anesthetics cannot. Supporting evidence for such a possibility
includes that ketamine, but not halothane, changed the chemical shift
of the pore-lining residue L9′ (Fig. 5) and ketamine affected themotions
of the α7 TM domain with a pattern different from that of halothane,
particularly in TM4 (Fig. 6).
It is worthmentioning that ketamine has been found to inhibit func-
tions of GLIC [67], a homologue of the α7 nAChR. Allosteric inhibition
was via ketamine binding to an inter-subunit cavity in the EC domain
of GLIC. It was shown (Fig. S5 [67]) that theα7 nAChRhas a homologous
cavity in the EC domain that mimics the ketamine-binding site in GLIC
[67]. Although the structural study for the α7 nAChR reported hereincludes only the TM domain, ketamine binding to the TM site as
identiﬁed in Fig. 5 and to the EC site as suggested previously [67] can
both contribute to functional inhibition of the α7 nAChR [51–53].
5. Conclusions
The high-resolution NMR structure for the α7 nAChR TM domain
determined in this study offers an invaluable structural framework for
designing new therapeutic modulators and for rationalizing extensive
biochemical and functional data collected previously on nAChRs. The
discovery of halothane binding to the α7 nAChR TM domain provides
convincing evidence that insensitivity of a pLGIC to anesthetics, such
as in the case of theα7 nAChR to volatile anesthetics [20,21], is not nec-
essarily due to a lack of anesthetic binding. Comparisons of halothane
sites in α7 with those in theα4β2 nAChR [54] and distinct dynamic re-
sponses of these receptors to halothane binding convey an important
message, that is, effective functional modulation occurs only when
the binding of anesthetics, or any modulators, induces dynamics or
conformational changes in the channel pore.
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